The Custom Pharmaceutical Services (CPS) facility of Dr Reddy’s Laboratories Ltd at its Technology Development Centre (TDC-1), Miyapur here has cleared the US Food and Drug Administration (USFDA) audit.
The audit of the facility "has been completed today with zero observations'',’ the Hyderabad-based company informed the bourses in an update on Thursday.
The company has also received an Establishment Inspection Report (EIR) from the USFDA for its formulation Srikakulum plant (SEZ) unit - II, Andhra Pradesh, according to the update.
Dr Reddy’s scrip was trading up by 7.11 per cent at Rs 2,478 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.